Temporal trends of time in therapeutic range and incidence of cardiovascular events in patients with non-valvular atrial fibrillation

被引:21
作者
Pastori, Daniele [1 ,2 ]
Farcomeni, Alessio [3 ]
Saliola, Mirella [1 ]
Del Sole, Francesco [1 ]
Pignatelli, Pasquale [1 ]
Violi, Francesco [1 ]
Lip, Gregory Y. H. [2 ,4 ]
机构
[1] Sapienza Univ Rome, Dept Internal Med & Med Specialties, Clin Med 1, Atherothrombosis Ctr, Rome, Italy
[2] Univ Birmingham, Inst Cardiovasc Sci, Birmingham, W Midlands, England
[3] Sapienza Univ Rome, Dept Publ Hlth & Infect Dis, Rome, Italy
[4] Aalborg Univ, Dept Clin Med, Aalborg Thrombosis Res Unit, Aalborg, Denmark
关键词
Atrial fibrillation; Anticoagulation; Vitamin K antagonists; Time in therapeutic range; Cardiovascular events; PROTON PUMP INHIBITORS; ANTICOAGULATION CONTROL; ORAL ANTICOAGULATION; WARFARIN; QUALITY; RISK; EFFICACY; ASPIRIN; STROKE; SAFETY;
D O I
10.1016/j.ejim.2018.04.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Optimal time in therapeutic range (TTR) of vitamin K antagonists (VKAs) is crucial for cardiovascular events (CVEs) prevention in non-valvular atrial fibrillation (NVAF). The relationship between temporal changes of TTR and the incidence of CVEs has been poorly investigated. We investigated 1) temporal trends of TTR in a long-term follow-up of NVAF patients; 2) the incidence of CVEs according to changes of TTR. Methods: Prospective observational study including 1341 NVAF outpatients (mean age 73.5 years, 42.5% male) starting VKAs. Patients were divided into 4 groups: Group 0: Optimal TTR, consistently >= 70% (n = 241); Group 1: Temporally worsening TTR, from above to below 70% (n = 263); Group 2: Temporally improving TTR, from below to above 70% (n = 270); Group 3: Suboptimal TTR, consistently < 70% (n = 567). Results: In a mean follow-up of 37.7 months (4214.2 patient-years), 108 CVEs occurred (2.6%/year). Survival analysis showed a graded increased risk of CVEs in relation to temporal changes in TTR, with the worst outcomes in Groups 1 and 3 (log-rank test p = 0.013). Multivariable Cox proportional hazards regression analysis showed that Group 1 vs. 0 (HR: 2.096; 95%CI 1.061-4.139, p = 0.033), Group 3 vs. 0 (HR: 2.292; 95%CI 1.205-4.361, p = 0.011), CHA(2)DS(2)VASc score (HR:1.316; 95%CI 1.153-1.501, p < 0.001) and PPIs (HR:0.453; 95%CI 0.285-0.721, p = 0.001) were independently associated with CVEs. Conclusion: A decrease of TTR < 70% over time is observed in almost 20% of NVAF patients. Patients with worsening TTR temporally (ie. from initially above 70% to below 70%) have similar risk of CVEs of patients with consistently suboptimal anticoagulation.
引用
收藏
页码:34 / 39
页数:6
相关论文
共 32 条
  • [21] Incidence of Myocardial Infarction and Vascular Death in Elderly Patients With Atrial Fibrillation Taking Anticoagulants Relation to Atherosclerotic Risk Factors
    Pastori, Daniele
    Pignatelli, Pasquale
    Angelico, Francesco
    Farcomeni, Alessio
    Del Ben, Maria
    Vicario, Tommasa
    Bucci, Tommaso
    Raparelli, Valeria
    Cangemi, Roberto
    Tanzilli, Gaetano
    Lip, Gregory Y. H.
    Violi, Francesco
    [J]. CHEST, 2015, 147 (06) : 1644 - 1650
  • [22] The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease
    Pastori, Daniele
    Polimeni, Licia
    Baratta, Francesco
    Pani, Arianna
    Del Ben, Maria
    Angelico, Francesco
    [J]. DIGESTIVE AND LIVER DISEASE, 2015, 47 (01) : 4 - 11
  • [23] Chronic Kidney Disease, Time in Therapeutic Range and Adverse Clinical Outcomes in Anticoagulated Patients with Non-valvular Atrial Fibrillation: Observations from the SPORTIF Trials
    Proietti, Marco
    Lane, Deirdre A.
    Lip, Gregory Y. H.
    [J]. EBIOMEDICINE, 2016, 8 : 309 - 316
  • [24] Adherence to oral anticoagulant therapy in patients with atrial fibrillation Focus on non-vitamin K antagonist oral anticoagulants
    Raparelli, Valeria
    Proietti, Marco
    Cangemi, Roberto
    Lip, Gregory Y. H.
    Lane, Deirdre A.
    Basili, Stefania
    [J]. THROMBOSIS AND HAEMOSTASIS, 2017, 117 (02) : 209 - 218
  • [25] Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients
    Rivera-Caravaca, Jose Miguel
    Roldan, Vanessa
    Asuncion Esteve-Pastor, Maria
    Valdes, Mariano
    Vicente, Vicente
    Lip, Gregory Y. H.
    Marin, Francisco
    [J]. THROMBOSIS AND HAEMOSTASIS, 2017, 117 (07) : 1448 - 1454
  • [26] Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA)
    Rose, A. J.
    Hylek, E. M.
    Ozonoff, A.
    Ash, A. S.
    Reisman, J. I.
    Berlowitz, D. R.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 (10) : 2182 - 2191
  • [27] ROSENDAAL FR, 1993, THROMB HAEMOSTASIS, V69, P236
  • [28] Safety and efficacy of well managed warfarin A report from the Swedish quality register Auricula
    Sjogren, Vilhelm
    Grzymala-Lubanski, Bartosz
    Renlund, Henrik
    Friberg, Leif
    Lip, Gregory Y. H.
    Svensson, Peter J.
    Sjalander, Anders
    [J]. THROMBOSIS AND HAEMOSTASIS, 2015, 113 (06) : 1370 - 1377
  • [29] Atrial Fibrillation and Acid Reflux Disease
    Velagapudi, Poonam
    Turagam, Mohit K.
    Leal, Miguel A.
    Kocheril, Abraham G.
    [J]. CLINICAL CARDIOLOGY, 2012, 35 (03) : 180 - 186
  • [30] Atrial Fibrillation and Myocardial Infarction: A Systematic Review and Appraisal of Pathophysiologic Mechanisms
    Violi, Francesco
    Soliman, Elsayed Z.
    Pignatelli, Pasquale
    Pastori, Daniele
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2016, 5 (05):